All Stories

  1. The last mile in onchocerciasis elimination: diagnostic challenges
  2. Community-directed treatment with ivermectin in Maridi, South Sudan: Impact of an onchocerciasis awareness campaign and bi-annual treatment on therapeutic coverage
  3. Utilization of health facilities and schools in onchocerciasis elimination efforts
  4. “The traditional healer said, ’I had a genie that scared me in my eyes, and that is why I fall“: An ethnographic study in Mahenge, Tanzania
  5. Usability, acceptability, and cost of the SD BIOLINE Ov16 rapid diagnostic test for onchocerciasis surveillance in endemic communities in the middle belt of Ghana
  6. Decreasing epilepsy-related mortality in the Maridi onchocerciasis focus, South Sudan
  7. A community-based vector control intervention “Slash and Clear” implemented in two onchocerciasis-endemic foci in South Sudan
  8. Public health priorities for mpox clade Ib in pregnant, breastfeeding, and paediatric populations in DR Congo
  9. Recognising the neurological burden of onchocerciasis: the need to include onchocerciasis-associated epilepsy in onchocerciasis global health metrics
  10. A Novel Biplex Onchocerca volvulus Rapid Diagnostic Test Evaluated Among 3- to 9-Year-Old Children in Maridi, South Sudan
  11. High prevalence of epilepsy associated with onchocerciasis in northern Uganda
  12. Pregnant Women, a Potential Reservoir for Onchocerca volvulus? A Cross Sectional Study in Maridi County, South Sudan
  13. A Novel Biplex<em> Onchocerca volvulus</em> Rapid Diagnostic Test: Feasibility and Comparison with the Ov16 SD Bioline Rapid Diagnostic Test Among 3–9-Year-Old Children in Maridi, South Sudan
  14. Cameroonian blackflies (Diptera: Simuliidae) harbour a plethora of RNA viruses
  15. Community‐based epilepsy care in an onchocerciasis‐endemic area: A 3‐year cohort study in Mahenge, Tanzania
  16. The Spectrum of Ocular Diseases in the Onchocerciasis-Endemic Focus of Raga in South Sudan
  17. Mpox outbreak—tecovirimat resistance, management approaches, and challenges in HIV-endemic regions
  18. Nakalanga syndrome and hypopituitarism
  19. Attitudes and perceptions towards epilepsy in an onchocerciasis-endemic region of Tanzania: a mixed approach to determine the magnitude and driving factors
  20. Prevalence of onchocerciasis and epilepsy in a Tanzanian region after a prolonged community-directed treatment with ivermectin
  21. Diverse RNA viruses of parasitic nematodes can elicit antibody responses in vertebrate hosts
  22. Onchocerciasis-associated epilepsy in Western Equatoria State, South Sudan
  23. Epidemiology of epilepsy in Wulu County, an onchocerciasis-endemic area in South Sudan
  24. Doxycycline, a role in the treatment of onchocerciasis-associated epilepsy?
  25. Robust epidemiological evidence supports the association between nodding syndrome and epilepsy
  26. Accelerating onchocerciasis elimination in humanitarian settings: lessons from South Sudan
  27. Modelling onchocerciasis-associated epilepsy and the impact of ivermectin treatment on its prevalence and incidence
  28. Mvolo County, an Onchocerciasis Endemic Area in Western Equatoria State, South Sudan: An Entomological Study to Prepare for a “Slash and Clear” Community-Based Vector Control Intervention
  29. Onchocerciasis-associated epilepsy and biomarkers
  30. Evaluating epilepsy management in an onchocerciasis-endemic area: Case of Maridi, South Sudan
  31. Onchocerciasis-associated epilepsy: Charting a path forward
  32. Nodding Syndrome Associated with Onchocerciasis
  33. Rapid diagnostic testing for onchocerciasis in Maridi (South Sudan) before and after improving elimination strategies: a repeated cross-sectional survey
  34. Impact of annual community-directed treatment with ivermectin on the incidence of epilepsy in Mvolo, a two-year prospective study
  35. Chorioretinitis among Immigrant and Travellers. Comment on Mansour et al. Presumed Onchocerciasis Chorioretinitis Spilling over into North America, Europe and Middle East. Diagnostics 2023, 13, 3626
  36. Treatment and prevention of epilepsy in onchocerciasis-endemic areas is urgently needed
  37. Integration of onchocerciasis morbidity management and disability prevention services in the healthcare system in Tanzania: a call for action and recommendations
  38. Methodological challenges for conducting case-control studies to investigate the association between onchocerciasis and epilepsy including nodding syndrome
  39. Onchocerciasis-associated epilepsy: an explorative case-control study with viral metagenomic analyses on Onchocerca volvulus
  40. Rapid diagnostic testing for onchocerciasis in Maridi (South Sudan) before and after improving elimination strategies: a repeated cross-sectional survey
  41. Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study
  42. Accessibility to formal education among persons with epilepsy in Mahenge, Tanzania
  43. Increased resources are needed in sub-Saharan Africa for epilepsy in older populations but also to prevent and treat epilepsy in the younger age groups
  44. Persistence of onchocerciasis and associated dermatologic and ophthalmic pathologies after 27 years of ivermectin mass drug administration in the middle belt of Ghana
  45. Onchocerciasis-associated epilepsy: an explorative case-control study with viral metagenomic analyses on Onchocerca volvulus
  46. Procedure for Handling and Storage of Onchocerca volvulus Microfilariae Obtained from Skin Snips for Downstream Genetic Work
  47. Disability assessment among persons with epilepsy in Mahenge, an onchocerciasis-endemic area in Tanzania: A cross-sectional study
  48. The onchocerciasis hypothesis of nodding syndrome
  49. Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin
  50. Mortality among persons with epilepsy in onchocerciasis-endemic and non-endemic areas of sub-Saharan Africa: A systematic review and meta-analysis
  51. Quality of life of persons with epilepsy in Mahenge, an onchocerciasis-endemic area in Tanzania: A cross-sectional study
  52. Effect of onchocerciasis elimination measures on the incidence of epilepsy in Maridi, South Sudan: a 3-year longitudinal, prospective, population-based study
  53. Assessing Onchocerca volvulus Intensity of Infection and Genetic Diversity Using Mitochondrial Genome Sequencing of Single Microfilariae Obtained before and after Ivermectin Treatment
  54. Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: A population-based prospective study
  55. Nodding syndrome, a case-control study in Mahenge, Tanzania: Onchocerca volvulus and not Mansonella perstans as a risk factor
  56. Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness
  57. ASSOCIATION OF ONCHOCERCIASIS NODULE PREVALENCE IN MOTHERS AND THE DEVELOPMENT OF EPILEPSY IN THEIR CHILDREN IN MAHENGE, AN ONCHOCERCIASIS-ENDEMIC AREA OF TANZANIA: A CASE-CONTROL STUDY
  58. Case definitions for onchocerciasis-associated epilepsy and nodding syndrome: A focused review
  59. Onchocerciasis-associated epilepsy: an update and future perspectives
  60. How to decrease the epilepsy disease burden in sub-Saharan Africa?
  61. Nodding Syndrome: Clinical Characteristics, Risks Factors, Access to Treatment, and Perceptions in the Greater Mundri Area, South Sudan
  62. Impact of COVID-19 on the well-being of children with epilepsy including nodding syndrome in Uganda: A qualitative study
  63. Nodding syndrome, populations at risk need to be aware this is a preventable condition
  64. Nodding Syndrome, a Case-control Study in Mahenge, Tanzania: <em>Onchocerca volvulus </em>and not <em>Mansonella </em><em>perstans</em> as Risk Factor
  65. COVID-19 in Low and Middle Income Countries
  66. Adherence to COVID-19 preventive measures in Sub-Saharan Africa during the 1st year of the pandemic: Pooled analysis of the International Citizen Project on COVID-19 (ICPCovid) surveys
  67. New vector of River blindness identified in Africa
  68. High Prevalence of Glaucoma among Patients in an Onchocerciasis Endemic Area (Mahenge, Tanzania)
  69. Enhanced surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the limitations of symptom-based case definitions
  70. Infectious Diseases Institute at Makerere University College of Health Sciences: a case study of a sustainable capacity building model for health care, research and training
  71. Community Knowledge, Attitudes and Practices Regarding Onchocerciasis in Rural Villages With a High Epilepsy Prevalence in Mahenge, Tanzania: A Qualitative Study
  72. Correction: Dusabimana et al. Surveillance for Onchocerciasis-Associated Epilepsy and Ov16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening. Pathogens 2022, 11, 281
  73. Immunoinformatics Design and Assessment of a Multiepitope Antigen (OvMCBL02) for Onchocerciasis Diagnosis and Monitoring
  74. Enhanced surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the limitations of symptom-based case definitions
  75. ‘There Were Moments We Wished She Could Just Die’: The Highly Gendered Burden of Nodding Syndrome in Northern Uganda
  76. Psychosocial Factors Associated With Adherence to COVID-19 Preventive Measures in Low-Middle- Income Countries, December 2020 to February 2021
  77. High COVID-19 Vaccine Acceptance among Eye Healthcare Workers in Uganda
  78. Ivermectin for malaria control in mass drug administration programmes
  79. The Prevalence of Onchocerciasis-Associated Epilepsy in Mundri West and East Counties, South Sudan: A Door-to-Door Survey
  80. Defining post-COVID condition
  81. Reducing onchocerciasis-associated morbidity in onchocerciasis-endemic foci with high ongoing transmission: a focus on the children.
  82. Community knowledge, attitudes, and practices regarding epilepsy in Mahenge, Tanzania: A socio-anthropological study in an onchocerciasis-endemic area with a high prevalence of epilepsy
  83. Impact of the COVID-19 pandemic on persons with epilepsy in Uganda: A descriptive cross-sectional study
  84. Using Andersen’s model of health care utilization to assess factors associated with COVID-19 testing among adults in nine low-and middle-income countries: an online survey
  85. Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening
  86. The Prevalence of Onchocerciasis-Associated Epilepsy in Mundri West and East Counties, South Sudan: A Door to Door Survey
  87. Community perception of epilepsy and its treatment in onchocerciasis-endemic villages of Maridi county, western equatoria state, South Sudan
  88. Adherence to COVID-19 Preventive Measures among Dental Care Workers in Vietnam: An Online Cross-Sectional Survey
  89. Prevalence and Risk Factors Associated with Epilepsy in Six Health Districts of Mali: A Community-Based Cross-Sectional and Nested Case-Control Study
  90. Cardiovascular risk factors and clinical outcomes of patients hospitalized with COVID-19 pneumonia in Somalia
  91. Adults’ Acceptance of COVID-19 Vaccine for Children in Selected Lower- and Middle-Income Countries
  92. Adherence to COVID-19 preventive measures among dental care workers in Vietnam: an online cross-sectional survey
  93. Treatment of Pregnant Women with Ivermectin during Mass Drug Distribution: Time to Investigate Its Safety and Potential Benefits
  94. Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis
  95. Risk Factors for Nodding Syndrome and Other Forms of Epilepsy in Northern Uganda: A Case-Control Study
  96. Onchocerca volvulus transmission in the Mbam valley of Cameroon following 16 years of annual community-directed treatment with ivermectin, and the description of a new cytotype of Simulium squamosum
  97. A peer support group intervention to decrease epilepsy-related stigma in an onchocerciasis-endemic area in Mahenge, Tanzania: A pilot study
  98. “Slash and Clear”, a Community-Based Vector Control Method to Reduce Onchocerciasis Transmission by Simulium sirbanum in Maridi, South Sudan: A Prospective Study
  99. Association Between Ov16 Seropositivity and Neurocognitive Performance Among Children in Rural Cameroon: a Pilot Study
  100. Ivermectin Should Not Be Recommended to Treat Severe Acute Respiratory Syndrome 2 Infection
  101. ‘Slash and clear’ vector control for onchocerciasis elimination and epilepsy prevention: a protocol of a cluster randomised trial in Cameroonian villages
  102. Epilepsy in the Sanaga‐Mbam valley, an onchocerciasis‐endemic region in Cameroon: electroclinical and neuropsychological findings
  103. COVID-19 Vaccine Acceptability and Its Determinants in Mozambique: An Online Survey
  104. Fear and depression during the COVID-19 outbreak in Cameroon: a nation-wide observational study
  105. Stress and Associated Factors among Frontline Healthcare Workers in the COVID-19 Epicenter of Da Nang City, Vietnam
  106. No Evidence for the Involvement of Leiomodin-1 Antibodies in the Pathogenesis of Onchocerciasis-Associated Epilepsy
  107. Extensive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Associated With Low Mortality in Kinshasa, Democratic Republic of the Congo: For How Long?
  108. No Evidence Known Viruses Play a Role in the Pathogenesis of Onchocerciasis-Associated Epilepsy. An Explorative Metagenomic Case-Control Study
  109. COVID-19 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey
  110. First description of Nodding Syndrome in the Central African Republic
  111. Impact of COVID-19 on Healthcare Workers in Brazil between August and November 2020: A Cross-Sectional Survey
  112. Serotonin Levels in the Serum of Persons with Onchocerciasis-Associated Epilepsy: A Case-Control Study
  113. COVID-19 Vaccine Acceptability and Adherence to Preventive Measures in Somalia: Results of an Online Survey
  114. Stress and associated factors among frontline healthcare workers in the COVID-19 epicenter of Da Nang city, Vietnam
  115. Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low- and Middle-Income Countries
  116. The World Health Organization road map for neglected tropical diseases 2021–2030: implications for onchocerciasis elimination programs
  117. High Prevalence of Epilepsy in an Onchocerciasis-Endemic Area in Mvolo County, South Sudan: A Door-To-Door Survey
  118. Intimate Partners Violence against Women during a COVID-19 Lockdown Period: Results of an Online Survey in 7 Provinces of the Democratic Republic of Congo
  119. Well-Being of Healthcare Workers and the General Public during the COVID-19 Pandemic in Vietnam: An Online Survey
  120. The Secretome of Filarial Nematodes and Its Role in Host-Parasite Interactions and Pathogenicity in Onchocerciasis-Associated Epilepsy
  121. Follow-Up Survey of the Impact of COVID-19 on People Living with HIV during the Second Semester of the Pandemic
  122. Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study
  123. COVID-19: The African Enigma
  124. Prevalence of Onchocerciasis-Associated Epilepsy in Mvolo County, South Sudan: A Door to Door Survey
  125. Vietnamese People’s Well-Being During the COVID-19 Pandemic: An Online Survey
  126. Onchocerciasis Prevalence among Persons with Epilepsy in an Onchocerciasis Hypo-Endemic Area in the Democratic Republic of Congo: A Cross-Sectional Study
  127. Potential Parasitic Causes of Epilepsy in an Onchocerciasis Endemic Area in the Ituri Province, Democratic Republic of Congo
  128. Violence and discrimination among Ugandan residents during the COVID-19 lockdown
  129. Cytokines and Onchocerciasis-Associated Epilepsy, a Pilot Study and Review of the Literature
  130. Adherence to COVID-19 Prevention Measures in the Democratic Republic of the Congo, Results of Two Consecutive Online Surveys
  131. COVID-19 Preventive Behaviours in Cameroon: A Six-Month Online National Survey
  132. Nodding syndrome research revisited
  133. Community perceptions and attitudes regarding epilepsy and disease cost after implementation of a community-based epilepsy treatment program in onchocerciasis-endemic communities in the Democratic Republic of Congo
  134. Impact of COVID-19 on the lives and psychosocial well-being of persons with epilepsy during the third trimester of the pandemic: Results from an international, online survey
  135. Determinants of Modern Contraceptive Methods (MCM) discontinuation among childbearing age women in Kinshasa, Democratic Republic of Congo.
  136. In pursuit of a cure: The plural therapeutic landscape of onchocerciasis-associated epilepsy in Cameroon – A mixed methods study
  137. COVID-19 Vaccine Acceptance in the Democratic Republic of Congo: A Cross-Sectional Survey
  138. Fear and Depression during the COVID-19 Outbreak in Cameroon: A Nation-wide Observational Study
  139. Adherence to COVID-19 Preventive Measures in Mozambique: Two Consecutive Online Surveys
  140. Neuropathological Changes in Nakalanga Syndrome—A Case Report
  141. COVID-19 outbreak in Brazil: adherence to national preventive measures and impact on people’s lives, an online survey
  142. Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation
  143. Adherence to COVID-19 Preventive Measures Prior to Vaccine Interventions: A Meta-Analysis of Online Surveys in Sub-Saharan Africa
  144. Assessment of adherence to public health measures and their impact on the COVID-19 outbreak in Benin Republic, West Africa
  145. Factors associated with adherence to COVID-19 prevention measures in the Democratic Republic of the Congo (DRC): results of an online survey
  146. Nodding syndrome, many questions remain but we can prevent it by eliminating onchocerciasis
  147. Lack of elevated pre-ART elastase-ANCA levels in patients developing TB-IRIS
  148. Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected with Onchocerca volvulus
  149. Case Report: Nakalanga Syndrome Revisited: Long-Term Follow-Up of a Patient Living in Western Uganda, 1994–2018
  150. Ivermectin Treatment Response in Two Rural Villages with a High Prevalence of Onchocerciasis and Epilepsy, Mahenge Tanzania
  151. Onchocerciasis-associated epilepsy an unrecognised important preventable public health problem
  152. Level and Determinants of Adherence to COVID-19 Preventive Measures in the First Stage of the Outbreak in Uganda
  153. Impact of the COVID-19 Pandemic on the Medical Follow-up and Psychosocial Well-Being of People Living With HIV: A Cross-Sectional Survey
  154. Access to healthcare and prevalence of anxiety and depression in persons with epilepsy during the COVID-19 pandemic: A multicountry online survey
  155. Changes in epilepsy burden after onchocerciasis elimination in a hyperendemic focus of western Uganda: a comparison of two population-based, cross-sectional studies
  156. Improving mental health and psychosocial wellbeing in humanitarian settings: reflections on research funded through R2HC
  157. OV16 Seroprevalence among Persons with Epilepsy in Onchocerciasis Endemic Regions: A Multi-Country Study
  158. Violence and Discrimination Among Ugandan Residents During the COVID-19 Lockdown
  159. A call for strengthened evidence on targeted, non-pharmaceutical interventions against COVID-19 for the protection of vulnerable individuals in sub-Saharan Africa
  160. Epilepsy-related stigma and cost in two onchocerciasis-endemic areas in South Sudan: A pilot descriptive study
  161. Vietnamese People’s Well-Being During the COVID-19 Pandemic: An Online Survey
  162. Vietnamese people’s well-being during the COVID-19 pandemic: an online survey 
  163. Preventive behavior of Vietnamese people in response to the COVID-19 pandemic
  164. COVID-19 in Somalia: Adherence to Preventive Measures and Evolution of the Disease Burden
  165. Mass masking as a way to contain COVID-19 and exit lockdown in low- and middle-income countries
  166. Evidence for significant COVID-19 community transmission in Somalia using a clinical case definition
  167. Ivermectin Treatment Response in Onchocerca Volvulus Infected Persons with Epilepsy: A Three-Country Short Cohort Study
  168. COVID-19 outbreak in Brazil: Adherence to national preventive measures and impact on people’s lives
  169. Le français innovant
  170. Comparison of Diagnostic Tests for Onchocerca volvulus in the Democratic Republic of Congo
  171. Dried Blood Microsampling-Based Therapeutic Drug Monitoring of Antiepileptic Drugs in Children With Nodding Syndrome and Epilepsy in Uganda and the Democratic Republic of the Congo
  172. Persons with onchocerciasis-associated epilepsy and nodding seizures have a more severe form of epilepsy with more cognitive impairment and higher levels of Onchocerca volvulus infection
  173. Preventive behavior of Vietnamese people in response to the COVID-19 pandemic
  174. From nodding syndrome to onchocerciasis-associated epilepsy
  175. Focus of Ongoing Onchocerciasis Transmission Close to Bangui, Central African Republic
  176. The Role of the Maridi Dam in Causing an Onchocerciasis-Associated Epilepsy Epidemic in Maridi, South Sudan: An Epidemiological, Sociological, and Entomological Study
  177. Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali
  178. Single versus Multiple Dose Ivermectin Regimen in Onchocerciasis-Infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo
  179. Meta-analysis of epilepsy prevalence in West Africa and its relationship with onchocerciasis endemicity and control
  180. Urinary N-acetyltyramine-O,β-glucuronide in Persons with Onchocerciasis-Associated Epilepsy
  181. Prevalence and incidence of nodding syndrome and other forms of epilepsy in onchocerciasis-endemic areas in northern Uganda after the implementation of onchocerciasis control measures
  182. Safety of ivermectin during pregnancy
  183. Onchocerca volvulus is not detected in the cerebrospinal fluid of persons with onchocerciasis-associated epilepsy
  184. Single Versus Multiple Dose Ivermectin Regimen in Onchocerciasis-infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo
  185. Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration
  186. Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial
  187. Ivermectin use in children below 15 kg: potential benefits for onchocerciasis and scabies elimination programmes
  188. Epilepsy prevention
  189. Nodding Syndrome
  190. Elimination of onchocerciasis in Africa by 2025: an ambitious target requires ambitious interventions
  191. Women with epilepsy in sub–Saharan Africa: A review of the reproductive health challenges and perspectives for management
  192. Clinical presentation of epilepsy in six villages in an onchocerciasis endemic area in Mahenge, Tanzania
  193. Emergomyces: The global rise of new dimorphic fungal pathogens
  194. Neuroinflammation and Not Tauopathy Is a Predominant Pathological Signature of Nodding Syndrome
  195. Analysis of the RIMDAMAL trial
  196. Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?
  197. Increased cost‐benefit of strengthening onchocerciasis elimination efforts in areas with high onchocerciasis‐associated epilepsy
  198. The efficacy of a brief intervention to reduce alcohol use in persons with HIV in South Africa, a randomized clinical trial
  199. From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes
  200. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density
  201. Low ivermectin use among 5- to 6-year-old children: observations from door-to-door surveys in onchocerciasis-endemic regions in Africa
  202. Onchocerciasis-associated epilepsy: another piece in the puzzle from the Mahenge mountains, southern Tanzania
  203. Stigma and epilepsy in onchocerciasis-endemic regions in Africa: a review and recommendations from the onchocerciasis-associated epilepsy working group
  204. Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
  205. Epidemiological evidence concerning the association between onchocerciasis and epilepsy
  206. Increased KLRG1 and PD-1 expression on CD8 T lymphocytes in TB-IRIS
  207. New filovirus disease classification and nomenclature
  208. Impact of 19 years of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon
  209. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density
  210. Economic Burden of Epilepsy in Rural Ituri, Democratic Republic of Congo
  211. Comprehensive management of epilepsy in onchocerciasis-endemic areas: lessons learnt from community-based surveys
  212. High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment
  213. Integrated seroprevalence-based assessment of Wuchereria bancrofti and Onchocerca volvulus in two lymphatic filariasis evaluation units of Mali with the SD Bioline Onchocerciasis/LF IgG4 Rapid Test
  214. Low prevalence of epilepsy and onchocerciasis after more than 20 years of ivermectin treatment in the Imo River Basin in Nigeria
  215. Nodding syndrome research, lessons learned from the NSETHIO project
  216. Clinical presentations of onchocerciasis-associated epilepsy (OAE) in Cameroon
  217. Intervention for reducing epilepsy-associated stigma
  218. The Effect of Onchocerciasis Elimination on Onchocerciasis-Associated Epilepsy in a Hyper-Endemic Focus of Western Uganda
  219. Effect of TB/HIV Integration on TB and HIV Indicators in Rural Ugandan Health Facilities
  220. Community perceptions of epilepsy and its treatment in an onchocerciasis endemic region in Ituri, Democratic Republic of Congo
  221. Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin
  222. High prevalence of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan: A community-based survey
  223. Oral Tecovirimat for the Treatment of Smallpox
  224. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
  225. The effect of bi-annual community-directed treatment with ivermectin on the incidence of epilepsy in onchocerciasis endemic villages in South Sudan: a study protocol
  226. Factors Influencing the Risk of Becoming Sexually Active Among HIV Infected Adolescents in Kampala and Kisumu, East Africa
  227. Clinical characteristics of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan
  228. The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study
  229. Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study
  230. Is nodding syndrome in northern Uganda linked to consumption of mycotoxin contaminated food grains?
  231. Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV–tuberculosis co-infected adults with low CD4+ cell counts
  232. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities
  233. Aberrant plasma MMP and TIMP dynamics in Schistosoma - Immune reconstitution inflammatory syndrome (IRIS)
  234. High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo
  235. Onchocerciasis associated epilepsy: An important neglected public health problem
  236. Epilepsy caused by onchocerciasis is an important public health problem in Africa
  237. High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20 years of community directed treatment with ivermectin
  238. Factors Associated with Wuchereria bancrofti Microfilaremia in an Endemic Area of Mali
  239. The blackfly vectors and transmission of Onchocerca volvulus in Mahenge, south eastern Tanzania
  240. Synergistic Impact of Training Followed by On-Site Support on HIV Clinical Practice: A Mixed-Design Study in Uganda With Pre/Post and Cluster-Randomized Trial Components
  241. Histological examination of post-mortem brains of children with nodding syndrome
  242. Considerations for Randomized Controlled Trials During Future Filovirus Outbreaks
  243. From river blindness control to elimination: bridge over troubled water
  244. Report of the first international workshop on onchocerciasis-associated epilepsy
  245. Evolution of epilepsy prevalence and incidence in a Tanzanian area endemic for onchocerciasis and the potential impact of community-directed treatment with ivermectin: a cross-sectional study and comparison over 28 years
  246. Molecular tests expedite the diagnosis of multidrug-resistant tuberculosis in childhood
  247. Onchocerciasis-Associated Epilepsy, an Additional Reason for Strengthening Onchocerciasis Elimination Programs
  248. Emergomyces africanus in Soil, South Africa
  249. Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome
  250. Molecular detection of airborne Emergomyces africanus, a thermally dimorphic fungal pathogen, in Cape Town, South Africa
  251. Elevated inflammatory cytokines in aqueous cytokine profile in HIV-1 infected patients with cataracts in Uganda
  252. Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda
  253. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
  254. High Prevalence of Onchocerciasis-Associated Epilepsy in Villages in Maridi County, Republic of South Sudan
  255. High mortality in non-Ebola virus disease cases: need to provide timely and effective care
  256. Attempted molecular detection of the thermally dimorphic human fungal pathogen Emergomyces africanus in terrestrial small mammals in South Africa
  257. Ivermectin Treatment in Patients With Onchocerciasis-Associated Epilepsy: Protocol of a Randomized Clinical Trial
  258. Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe–Africa Research Network for the Evaluation of Second-line Therapy trial
  259. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
  260. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study
  261. High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo
  262. The predicament of patients with suspected Ebola
  263. Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert® MTB/RIF era: a cohort study
  264. Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia
  265. Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment — 10 Countries, 2004–2015
  266. Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda
  267. Onchocerciasis-associated epilepsy: From recent epidemiological and clinical findings to policy implications
  268. First HIV prevalence estimates of a representative sample of adult sub-Saharan African migrants in a European city. Results of a community-based, cross-sectional study in Antwerp, Belgium
  269. Relationship Between Time to Initiation of Antiretroviral Therapy and Treatment Outcomes: A Cohort Analysis of ART Eligible Adolescents in Zimbabwe
  270. Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys
  271. Body Mass Index and Waist Circumference in Patients with HIV in South Africa and Associated Socio-demographic, Health Related and Psychosocial Factors
  272. Nodding syndrome: Preventable and treatable
  273. Persons living with HIV infection on antiretroviral therapy also consulting traditional healers: a study in three African countries
  274. AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions
  275. Nodding syndrome, other forms of epilepsy, and the Nakalanga syndrome most likely directly or indirectly caused by Onchocerca volvulus
  276. Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial
  277. Weight status and associated factors among HIV infected people on antiretroviral therapy in rural Dikgale, Limpopo, South Africa
  278. Is Plasmodium Species Parasitemia Really Associated With Increased Survival in Ebola Virus–Infected Patients?
  279. PrEP for African migrants in Europe? A research agenda
  280. Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa
  281. Overlooking the importance of immunoassays – Authors' reply
  282. Effect of On-Site Support on Laboratory Practice for Human Immunodeficiency Virus, Tuberculosis, and Malaria Testing
  283. Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)
  284. Effectiveness of educational outreach in infectious diseases management: a cluster randomized trial in Uganda
  285. Risk factors for epilepsy in Bas-Uélé Province, Democratic Republic of the Congo: a case–control study
  286. Nodding Syndrome in Onchocerciasis Endemic Areas
  287. Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa
  288. High-risk alcohol use and associated socio-demographic, health and psychosocial factors in patients with HIV infection in three primary health care clinics in South Africa
  289. Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda
  290. Essentials of filoviral load quantification
  291. Prevalence of River Epilepsy in the Orientale Province in the Democratic Republic of the Congo
  292. Nodding syndrome and epilepsy in onchocerciasis endemic regions: comparing preliminary observations from South Sudan and the Democratic Republic of the Congo with data from Uganda
  293. TOGETHER Project to Increase Understanding of the HIV Epidemic Among Sub-Saharan African Migrants: Protocol of Community-Based Participatory Mixed-Method Studies
  294. Implementation and Operational Research
  295. Nodding syndrome—we can now prevent it
  296. Reasons for Missing Antiretroviral Therapy: Results from a Multi-Country Study in Tanzania, Uganda, and Zambia
  297. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
  298. Reply to “A Word of Caution in Considering the Use of the Lipoarabinomannan Lateral Flow Assay on Cerebrospinal Fluid for Detection of Tuberculous Meningitis”
  299. Temporal trends in death causes in adults attending an urban HIV clinic in Uganda: a retrospective chart review
  300. A Critical Appraisal of the Ideology of Monogamy’s Influence on HIV Epidemiology
  301. Systematic screening for drug-resistant tuberculosis with Xpert® MTB/RIF in a referral hospital in Cambodia
  302. Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross sectional study
  303. Lower Levels of Antiretroviral Therapy Enrollment Among Men with HIV Compared with Women — 12 Countries, 2002–2013
  304. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study
  305. Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings
  306. Effect of Educational Outreach Timing and Duration on Facility Performance for Infectious Disease Care in Uganda: A Trial with Pre-Post and Cluster Randomized Controlled Components
  307. Nodding Syndrome May Be Only the Ears of the Hippo
  308. The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field
  309. Challenges from Tuberculosis Diagnosis to Care in Community-Based Active Case Finding among the Urban Poor in Cambodia: A Mixed-Methods Study
  310. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study
  311. Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome
  312. Accuracy of Lipoarabinomannan and Xpert MTB/RIF Testing in Cerebrospinal Fluid To Diagnose Tuberculous Meningitis in an Autopsy Cohort of HIV-Infected Adults
  313. Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series
  314. Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda
  315. Behaviour, not mobility, is a risk factor for HIV
  316. La dia-variation en français actuel
  317. Is Urinary Lipoarabinomannan the Result of Renal Tuberculosis? Assessment of the Renal Histology in an Autopsy Cohort of Ugandan HIV-Infected Adults
  318. Malaria Care in Infants Aged under Six Months in Uganda: An Area of Unmet Needs!
  319. Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy
  320. Filovirus epidemic in 1956 in Bili, DRC
  321. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study
  322. Large-scale Convalescent Blood and Plasma Transfusion Therapy for Ebola Virus Disease
  323. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia
  324. Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient
  325. Is frontloaded sputum microscopy an option in active tuberculosis case finding?
  326. Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings
  327. Correlates of concurrency among young people in Carletonville, South Africa
  328. Antiretroviral Treatment Program Retention among HIV-Infected Children in the Democratic Republic of Congo
  329. Practice of percutaneous needle autopsy; a descriptive study reporting experiences from Uganda
  330. Antigen-Specific Interferon-Gamma Responses and Innate Cytokine Balance in TB-IRIS
  331. Nodding syndrome since 2012: recent progress, challenges and recommendations for future research
  332. Priorities for Ebola virus disease response in west Africa
  333. Disease diagnosis in primary care in Uganda
  334. Cost-Effectiveness of Socioeconomic Support as Part of HIV Care for the Poor in an Urban Community-Based Antiretroviral Program in Uganda
  335. Needle Autopsy to Establish the Cause of Death in HIV-Infected Hospitalized Adults in Uganda
  336. Nodding syndrome—a new hypothesis and new direction for research
  337. Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia
  338. Concentration of Lymph Node Aspirate Improves the Sensitivity of Acid Fast Smear Microscopy for the Diagnosis of Tuberculous Lymphadenitis in Jimma, Southwest Ethiopia
  339. CD4 T-cell activation and reduced regulatory T-cell populations are associated with early development of cataracts among HIV-infected adults in Uganda
  340. Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
  341. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
  342. Migration intensity has no effect on peak HIV prevalence: an ecological study
  343. Delays in diagnosis and treatment of pulmonary tuberculosis in Wakiso and Mukono districts, Uganda
  344. A non-synonymous polymorphism in IL-23R Gene (rs1884444) is associated with reduced risk to schistosomiasis-associated Immune Reconstitution Inflammatory Syndrome in a Kenyan population
  345. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
  346. Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation
  347. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations
  348. Cardiovascular risk factors in a treatment-naïve, human immunodeficiency virus-infected rural population in Dikgale, South Africa
  349. Early Tracking after a Missed Return Visit Reduces the Proportion of Untraceable Patients at a Large HIV Clinic in Kampala, Uganda
  350. Two year mortality and associated factors in a cohort of children from rural Uganda
  351. Community-Based Active Tuberculosis Case Finding in Poor Urban Settlements of Phnom Penh, Cambodia: A Feasible and Effective Strategy
  352. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study
  353. Patients who return to care after tracking remain at high risk of attrition: experience from a large HIV clinic, Uganda
  354. Health Outcomes of Infants in a PMTCT Program in Kinshasa
  355. Deteriorating renal function and clinical outcomes in HIV-positive persons
  356. Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe
  357. Effect of Integrated Capacity-Building Interventions on Malaria Case Management by Health Professionals in Uganda: A Mixed Design Study with Pre/Post and Cluster Randomized Trial Components
  358. The Association between Female Genital Cutting and Spousal HCV Infection in Egypt
  359. The role of monocytes in the development of Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome
  360. LPS-Binding Protein and IL-6 Mark Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome in HIV Patients
  361. Does the CHER trial open up new therapeutic perspectives?
  362. Increase in numbers and proportions of review articles in Tropical Medicine, Infectious Diseases, and oncology
  363. Evaluation of the 2007 WHO guideline to diagnose smear negative tuberculosis in an urban hospital in Ethiopia
  364. Predictors of Mortality among Tuberculosis/HIV-Coinfected Persons in Southwest Ethiopia
  365. Acceptability of HIV self-testing: a systematic literature review
  366. Implementation of tuberculosis infection control in health facilities in Mukono and Wakiso districts, Uganda
  367. Burden of tuberculosis disease among adolescents in a rural cohort in Eastern Uganda
  368. Factors before enrolment are associated with being removed from a Pharmacy-only Refill Programme at a large urban HIV/AIDS clinic, Uganda
  369. Partner-concurrency associated with herpes simplex virus 2 infection in young South Africans
  370. Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome
  371. THE IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: A CAUSE OF DEATH IN PERSONS ON ANTIRETROVIRAL THERAPY?
  372. Antiretrovirals During Pregnancy: A Note of Caution
  373. Determinants of generalized herpes simplex virus-2 epidemics: the role of sexual partner concurrency
  374. Peak HIV prevalence: a useful outcome variable for ecological studies
  375. Change in quality of life: a follow up study among patients with HIV infection with and without TB in Ethiopia
  376. Antiretroviral Drug Resistance Profiles and Response to Second-Line Therapy Among HIV Type 1-Infected Ugandan Children
  377. Birds of a feather: homophily and sexual network structure in sub-Saharan Africa
  378. Hyperlactatemia and concurrent use of antiretroviral therapy among HIV infected patients in Uganda
  379. Ellipse et fragment
  380. Clinical Manifestations and Case Management of Ebola Haemorrhagic Fever Caused by a Newly Identified Virus Strain, Bundibugyo, Uganda, 2007–2008
  381. Design of a cluster randomized trial assessing integrated infectious diseases training and on-site support for midlevel practitioners in Uganda
  382. Response to Antiretroviral Therapy of HIV Type 1-Infected Children in Urban and Rural Settings of Uganda
  383. Determinants of male involvement in maternal and child health services in sub-Saharan Africa: a review
  384. Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia
  385. Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?
  386. Low prevalence of vitamin D deficiency in Ugandan HIV-infected patients with and without tuberculosis
  387. Strong association between point-concurrency and national peak HIV prevalence
  388. Utilization of HIV and Tuberculosis Services by Health Care Workers in Uganda: Implications for Occupational Health Policies and Implementation
  389. The efficacy of a brief intervention to reduce alcohol misuse in patients with HIV in South Africa: study protocol for a randomized controlled trial
  390. Depression and Posttraumatic Stress Disorder Among HIV-Infected Gambians on Antiretroviral Therapy
  391. Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome
  392. What Is the Optimal First Line Antiretroviral Therapy in Resource-Limited Settings?
  393. The Role of Raltegravir in the Treatment of HIV-2 Infections: Evidence from a Case Series
  394. Retention in a NGO Supported Antiretroviral Program in the Democratic Republic of Congo
  395. Tuberculosis lymphadenitis in Southwest Ethiopia: a community based cross-sectional study
  396. Sub-Optimal Vitamin B-12 Levels among ART-Naïve HIV-Positive Individuals in an Urban Cohort in Uganda
  397. Clinical Spectrum, Risk Factors and Outcome of Immune Reconstitution Inflammatory Syndrome in Patients with Tuberculosis–HIV Coinfection
  398. Corticosteroid Therapy, Vitamin D Status, and Inflammatory Cytokine Profile in the HIV-Tuberculosis Immune Reconstitution Inflammatory Syndrome
  399. Return to Normal Life After AIDS as a Reason for Lost to Follow-up in a Community-Based Antiretroviral Treatment Program
  400. Predictors of condom use and refusal among the population of Free State province in South Africa
  401. Strategies for Optimizing Clinic Efficiency in a Community-Based Antiretroviral Treatment Programme in Uganda
  402. PhDs: Adapt training for developing world
  403. Socioeconomic Support Reduces Nonretention in a Comprehensive, Community-Based Antiretroviral Therapy Program in Uganda
  404. An Autopsy Study Describing Causes of Death and Comparing Clinico-Pathological Findings among Hospitalized Patients in Kampala, Uganda
  405. Prevalence of pulmonary TB and spoligotype pattern of Mycobacterium tuberculosis among TB suspects in a rural community in Southwest Ethiopia
  406. A Randomized Controlled Trial to Evaluate the Effectiveness of a Board Game on Patients' Knowledge Uptake of HIV and Sexually Transmitted Diseases at the Infectious Diseases Institute, Kampala, Uganda
  407. A Tale Of Two Epidemics Within TWO Countries
  408. Predictors of antiretroviral treatment-associated tuberculosis in Ethiopia: a nested case-control study
  409. Interventions to reduce mortality in sub-Saharan Africa among HIV-infected adults not yet on antiretroviral therapy
  410. Immune Reconstitution Inflammatory Syndrome in HIV/AIDS
  411. Urinary Lipoarabinomannan as Predictor for the Tuberculosis Immune Reconstitution Inflammatory Syndrome
  412. Filovirus Hemorrhagic Fever Outbreak Case Management: A Review of Current and Future Treatment Options
  413. The immune reconstitution inflammatory syndrome related to HIV co-infections: a review
  414. Antiretroviral treatment in the private sector in Namibia
  415. Incidence and Predictors of Mortality and the Effect of Tuberculosis Immune Reconstitution Inflammatory Syndrome in a Cohort of TB/HIV Patients Commencing Antiretroviral Therapy
  416. Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy
  417. Association of haptoglobin phenotypes with the development of Kaposi’s sarcoma in HIV patients
  418. Electronic Medical Records and Same Day Patient Tracing Improves Clinic Efficiency and Adherence to Appointments in a Community Based HIV/AIDS Care Program, in Uganda
  419. Reducing mortality from HIV infection and tuberculosis
  420. Tuberculosis knowledge, attitudes and health-seeking behaviour in rural Uganda
  421. Sexual Satisfaction Among Men Living with HIV in Europe
  422. Autopsy acceptance rate and reasons for decline in Mulago Hospital, Kampala, Uganda
  423. Proposal to Adjust the WHO Clinical Staging System
  424. Cured of fear of flying
  425. Male partner voluntary counselling and testing associated with the antenatal services in Kinshasa, Democratic Republic of Congo: a randomized controlled trial
  426. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort
  427. Tuberculosis drug resistance testing by molecular methods: Opportunities and challenges in resource limited settings
  428. Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
  429. AWARENESS OF HEPATITIS C INFECTION AMONG MEN WHO HAVE SEX WITH MEN IN FLANDERS, BELGIUM
  430. Thoraco-abdominal Wall Reconstruction after Surgical Debulking of a Giant Retroperitoneal Liposarcoma: a Case Report
  431. Body Weight Changes and Clinical Outcome in Adults on Antiretroviral Therapy in Countries With Limited Resources
  432. The immune reconstitution inflammatory syndrome and antiretroviral therapy
  433. Nutritional Supplementation in HIV‐Infected Individuals Can Be Beneficial in Certain Patient Groups
  434. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin
  435. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions
  436. Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy
  437. Challenges in the diagnosis of meningitis in low-resource settings
  438. Knowledge, Health Seeking Behavior and Perceived Stigma towards Tuberculosis among Tuberculosis Suspects in a Rural Community in Southwest Ethiopia
  439. Sexual Protection Behavior in HIV-Positive Gay Men: Testing a Modified Information-Motivation-Behavioral Skills Model
  440. ART in low-resource settings: how to do more with less
  441. Alcohol and Antiretroviral Adherence? What About Africa?
  442. Common mental disorders in TB/HIV co-infected patients in Ethiopia
  443. Prejudice and misconceptions about tuberculosis and HIV in rural and urban communities in Ethiopia: a challenge for the TB/HIV control program
  444. Mirror, mirror on the wall: the face of HIV + women in Europe today
  445. Buruli Ulcer Lesions in HIV-Positive Patient
  446. Predictors of HIV Testing among Patients with Tuberculosis in North West Ethiopia: A Case-Control Study
  447. The International Index of Erectile Function: Development of an Adapted Tool for Use in HIV-Positive Men Who Have Sex with Men
  448. Role of the CD4 count in HIV management
  449. The Prevalence and Causes of Visual Loss Among HIV-Infected Individuals in Uganda
  450. Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
  451. “It's Better Not To Know”: Perceived Barriers to HIV Voluntary Counseling and Testing among Sub-Saharan African Migrants in Belgium
  452. Tuberculosis and HIV co-infection: its impact on quality of life
  453. Provider-initiated HIV testing for paediatric inpatients and their caretakers is feasible and acceptable
  454. An Algorithm to Optimize Viral Load Testing in HIV-Positive Patients With Suspected First-Line Antiretroviral Therapy Failure in Cambodia
  455. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia
  456. Pediatric HIV: new opportunities to treat children
  457. Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
  458. HIV-1-Infected Individuals Traveling to Malaria Endemic Areas
  459. Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need?
  460. Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine
  461. Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead
  462. Coping with TB immune reconstitution inflammatory syndrome
  463. Response to “Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES Genes”
  464. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria
  465. Impact of HIV-1 Infection on the Hematological Recovery After Clinical Malaria
  466. Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, Uganda
  467. Clinical presentation and aetiologies of acute or complicated headache among HIV-seropositive patients in a Ugandan clinic
  468. Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?
  469. Mortality and Associated Factors After Initiation of Pediatric Antiretroviral Treatment in the Democratic Republic of the Congo
  470. Three-Year Outcome Data of Second-Line Antiretroviral Therapy in Ugandan Adults: Good Virological Response but High Rate of Toxicity
  471. Biology and Natural History of Acquired Immunodeficiency Syndrome
  472. Fatal and Fulminant Infections
  473. A Visual Dosing Aid for First-line Pediatric Antiretroviral Treatment in Resource-poor Settings
  474. Differences in perceptions on sexual and reproductive health between service providers and people living with HIV: A qualitative elicitation study
  475. Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial
  476. Universal access to HIV care: pitfalls and the way forward
  477. Drug-resistant TB and HIV in resource-limited settings: what TB/HIV programmes can learn from each other
  478. Fever After a Stay in the Tropics: Clinical Spectrum and Outcome in HIV-Infected Travelers and Migrants
  479. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
  480. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance
  481. HIV education for health-care professionals in high prevalence countries: time to integrate a pre-service approach into training
  482. Immune restoration disease
  483. Determination of the Incidence of Tuberculosis in Low‐Income Countries
  484. HIV care and treatment for children in resource-limited settings
  485. Pediatric HIV infection: the state of antiretroviral therapy
  486. Sexual risk reduction needs of adolescents living with HIV in a clinical care setting
  487. Computed CD4 percentage as a low-cost method for determining pediatric antiretroviral treatment eligibility
  488. Increased Risk for Entamoeba histolytica Infection and Invasive Amebiasis in HIV Seropositive Men Who Have Sex with Men in Taiwan
  489. Evaluation of the GIDEON Expert Computer Program for the Diagnosis of Imported Febrile Illnesses
  490. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?
  491. Marburg Hemorrhagic Fever in Durba and Watsa, Democratic Republic of the Congo: Clinical Documentation, Features of Illness, and Treatment
  492. Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough?
  493. Current Hemoglobin Levels Are More Predictive of Disease Progression Than Hemoglobin Measured at Baseline in Patients Receiving Antiretroviral Treatment for HIV Type 1 Infection
  494. Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy
  495. Pulmonary cystic disease in HIV positive individuals in the Democratic Republic of Congo: three case reports
  496. Sexual dysfunction in HIV-positive men is multi-factorial: A study of prevalence and associated factors
  497. Vena cava inferior thrombosis detected by venous hum: a case report
  498. Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen
  499. When to switch for antiretroviral treatment failure in resource-limited settings?
  500. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV/TB CO-INFECTED PATIENT FOUR YEARS AFTER STARTING ANTIRETROVIRAL THERAPY
  501. Quality of Life in HIV Clinical Trials: Why Sexual Health Must Not Be Ignored
  502. Selective ambulatory management of imported falciparum malaria: a 5-year prospective study
  503. Tuberculosis in resource poor countries
  504. Assessment of the patient flow at the infectious diseases institute out-patient clinic, Kampala, Uganda
  505. Fever After a Stay in the Tropics
  506. HIV‐1 Immune Suppression and Antimalarial Treatment Outcome in Zambian Adults with Uncomplicated Malaria
  507. Remote consultations and HIV/AIDS continuing education in low-resource settings
  508. Réponse des auteurs
  509. Marburg Hemorrhagic Fever Associated with Multiple Genetic Lineages of Virus
  510. Etiology and Outcome of Fever After a Stay in the Tropics
  511. Authors' reply
  512. The Added Value of a CD4 Count to Identify Patients Eligible for Highly Active Antiretroviral Therapy Among HIV-Positive Adults in Cambodia
  513. HIV Eosinophilic Folliculitis in Uganda
  514. IMPORTED NON–PLASMODIUM FALCIPARUM MALARIA: A FIVE-YEAR PROSPECTIVE STUDY IN A EUROPEAN REFERRAL CENTER
  515. Infectious Mononucleosis–Like Syndromes in Febrile Travelers Returning From the Tropics
  516. Unexpected improvement of sexual dysfunction during atazanavir therapy
  517. Imported Katayama fever: Clinical and biological features at presentation and during treatment
  518. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins
  519. PORTAL VEIN THROMBOSIS IN A PATIENT WITH HIV TREATED WITH A PROTEASE INHIBITOR-CONTAINING REGIMEN
  520. Reply to Lawn and Wood
  521. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries
  522. Mycobacterium-associated immune reconstitution disease: macrophages running wild?
  523. Review editorial: Prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment
  524. Response to ‘Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?’ AIDS, 22 July 2005
  525. Pulmonary Sporothrix schenckii Infection in a HIV Positive Child
  526. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk
  527. Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time
  528. Corrélations anatomo-biologiques dans un cas de fièvre jaune importé de Gambie
  529. Free Antiretrovirals Must Not Be Restricted Only to Treatment-Naive Patients
  530. Palliative care in sub-Saharan Africa
  531. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium
  532. Rolling Out Antiretrovirals in Africa: There Are Still Challenges Ahead
  533. Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression
  534. BILATERAL BLINDNESS AFTER STARTING HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT IN A PATIENT WITH HIV INFECTION AND CRYPTOCOCCAL MENINGITIS
  535. Risk factors for and types of oesophageal cancer
  536. Merkel cell carcinoma and multiple basal cell carcinoma in an African albino woman with HIV infection
  537. Efavirenz-Associated Stevens-Johnson Syndrome
  538. Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection
  539. Five-year immunological outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre
  540. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment
  541. Families affected by HIV: Parents’ and children's characteristics and disclosure to the children
  542. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe
  543. Organisation of health care during an outbreak of Marburg haemorrhagic fever in the Democratic Republic of Congo, 1999
  544. Development, Evaluation, and Validation of an Oligonucleotide Probe Hybridization Assay To Subtype Human Immunodeficiency Virus Type 1 Circulating Recombinant Form CRF02_AG
  545. Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
  546. Mixed Arterial and Venous Thromboembolism in a Person with HIV Infection
  547. Risk Factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo
  548. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir
  549. The use of complementary and alternative medicine by persons with HIV infection in Europe
  550. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases
  551. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment
  552. Current thinking on the management of tuberculosis
  553. Editorial: Giving antiretrovirals in the peripartum period to prevent mother-to-child HIV transmission in low-income countries: only a short-term stopgap measure
  554. Multiple Tuberculous Brain Abscesses in an HIV-Infected Patient Successfully Treated with HAART and Antituberculous Treatment
  555. Human and simian immunodeficiency virus-infected chimpanzees do not have increased intracellular levels of ?-chemokines in contrast to infected humans
  556. Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives?
  557. HIV and sexual dysfunction
  558. FEVER AFTER A STAY IN THE TROPICS
  559. FEVER AFTER A STAY IN THE TROPICS
  560. Regional and temporal changes in AIDS in Europe before HAART
  561. A Belgian Traveler Who Acquired Yellow Fever in The Gambia
  562. Short communication: A cluster of Marburg virus disease involving an infant*
  563. Financial situation of people living with HIV in Europe
  564. IMPORTED VIRAL HAEMORRHAGIC FEVER WITH A POTENTIAL FOR PERSON-TO-PERSON TRANSMISSION : REVIEW AND RECOMMENDATIONS FOR INITIAL MANAGEMENT OF A SUSPECTED CASE IN BELGIUM
  565. DEVELOPMENT OF MULTIPLE ABSCESSES IN AN HIV/TB CO-INFECTED PATIENT AFTER INITIATION OF ANTITUBERCULOUS AND HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
  566. PATIENTS WITH HIV INFECTION AND FEVER: A DIAGNOSTIC APPROACH
  567. Self-reported signs of lipodystrophy by persons living with HIV infection
  568. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression
  569. Management of co-infection with HIV and TB
  570. Do Patents Prevent Access to Drugs for HIV in Developing Countries?
  571. Neuropsychiatric reaction induced by clarithromycin
  572. A Multidrug, Including Voriconazole, Resistant Oral Candida Infection in an AIDS Patient Effectively Treated with Echinocandin
  573. Rheumatological complications associated with the use of indinavir and other protease inhibitors
  574. Direct costs of health care for HIV/AIDS patients in Belgium
  575. Imported case of confirmed yellow fever detected in Belgium
  576. Diagnosis at first glance: nodular hepatic lesions in persons with AIDS
  577. Hospital based clinical surveillance for dengue haemorrhagic fever in Bandung, Indonesia 1994–1995
  578. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment
  579. Hospital services for people with HIV infection in Flanders: Patients' satisfaction
  580. Predominance of HIV Type 1 Subtype G among Commercial Sex Workers from Kinshasa, Democratic Republic of Congo
  581. Book: HIV
  582. Antiretroviral treatments used among adults with HIV infection in Europe
  583. Participants in HIV clinical trials in Europe
  584. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: A partial solution to Africa's HIV/AIDS problem?
  585. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB)
  586. Utilization of healthcare services by people living with HIV/AIDS in Europe
  587. A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression
  588. AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal
  589. Natural Residues versus Antiretroviral Drug-Selected Mutations in HIV Type 1 Group O Reverse Transcriptase and Protease Related to Virological Drug Failurein Vivo
  590. Near Full-Length Genome Analysis of HIV Type 1 CRF02.AG, Subtype C and CRF02.AG Subtype G Recombinants
  591. Curly Hair and Lipodystrophy as a Result of Highly Active Antiretroviral Treatment?
  592. LETTERS TO THE EDITOR
  593. Impact of New Developments in Antiretroviral Treatment on AIDS Prevention and Care in Resource-Poor Countries
  594. Viewpoint: Filovirus haemorrhagic fever outbreaks: much ado about nothing?
  595. Cutaneous Ulcer Caused by Mycobacterium avium and Recurrent Genital Herpes After Highly Active Antiretroviral Therapy
  596. Ebola Haemorrhagic Fever – a Review
  597. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates
  598. Multicentric Castleman’s Disease in 2 Patients with HIV Infection, Unresponsive to Antiviral Therapy
  599. Q Fever After A Journey In Syria: A Diagnosis Suggested by Bone Marrow Biopsy
  600. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy
  601. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection
  602. Euthanasia and End-of-Life Care
  603. Treatment and Prevention of Multidrug-Resistant Tuberculosis
  604. Sequence Note: HIV Type 1 C2V3 env Diversity among Belgian Individuals
  605. Recurrence of blackwater fever: triggering of relapses by different antimalarials
  606. Painful hyperaesthesia caused by protease inhibitors?
  607. Deafness Caused by Didanosine
  608. Cross-sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)-seropositive population: predisposing factors, epidemiology and antifungal susceptibility
  609. Deafness caused by didanosine
  610. Splenic Rupture as a Complication ofP. FalciparumMalaria After Residence in The Tropics. Report of Two Cases.
  611. Eosinophilia in Patients Infected with Human Immunodeficiency Virus
  612. Histoplasma Capsulatum Infection in Three AIDS Patients Living in Africa
  613. Bordetella pertussis as a cause of chronic respiratory infection in an AIDS patient
  614. HIV diagnosis delay in Antwerp, Belgium.
  615. The Interleukin-2 Receptor Subunit Expression and Function on Peripheral Blood Lymphocytes from HIV-Infected and Control Persons
  616. Surveillance case definition for AIDS in resource-poor countries
  617. Priorities for HIV testing in developing countries?
  618. Bibliographie
  619. Imported Relapsing Fever in European Tourists
  620. Orthostatic hypotension in HIV infection in Africa
  621. Pulmonary T-Cell Lymphoma in a Patient with the Acquired Immunodeficiency Syndrome
  622. The Prevalence of Hairy Leukoplakia in HIV Seropositive and HIV Seronegative Immunocompromised Patients
  623. Psoriasis regression in terminal AIDS
  624. An African Patient With Aids And Linitis Plastica
  625. For debate. AIDS surveillance in Africa: a reappraisal of case definitions.
  626. Increased Mortality and Tuberculosis Treatment Failure Rate among Human Immunodeficiency Virus (HIV) Seropositive Compared with HIV Seronegative Patients with Pulmonary Tuberculosis Treated with “Standard” Chemotherapy in Kinshasa, Zaire
  627. Seroconversion Rate, Mortality, and Clinical Manifestations Associated with the Receipt of a Human Immunodeficiency Virus-Infected Blood Transfusion in Kinshasa, Zaire
  628. Treatment for Kaposi's sarcoma in HIV-negative, non-homosexual men
  629. Mefloquine-induced Stevens-Johnson syndrome
  630. The association between malaria, blood transfusions, and HIV seropositivity in a pediatric population in Kinshasa, Zaire
  631. BCG Vaccine Abscesses Are Unrelated to HIV Infection
  632. Association Between HTLV-III/ LAV Infection and Tuberculosis in Zaire
  633. Carcinoid Heart Disease
  634. Carcinoid heart disease
  635. Opportunistic Infections
  636. Onchocerciasis-associated epilepsy pathogenesis and diagnostic tools for onchocerciasis elimination
  637. Epidemiological studies of onchocerciasis in Ghana : insights from Ghana's Middle Belt and challenges in attaining elimination
  638. Onchocerciasis associated epilepsy in South Sudan, an epidemiological, social and entomological study